Floatz logo

Irinotecan

Anaplastic Glioma

City of Hope Medical CenterSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Anaplastic Glioma cohort.

Asset / SponsorPhaseRating
Sorafenib
Virginia Commonwealth University
Phase 2BB
Everolimus
Nationwide Children's Hospital
Phase 2B
o6-benzylguanine
Duke University
Phase 2B
g207
Pediatric Brain Tumor Consortium
Phase 2CCC
Vorinostat
M.D. Anderson Cancer Center
Phase 1/2CCC
Isotretinoin
M.D. Anderson Cancer Center
Phase 1/2CCC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 1/2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →